New drug combo with chemo for advanced stomach cancer
Treatments studied
Part of Cancer clinical trials.
This study tests a combination of two experimental drugs (QLS31905 and QL2107) plus chemotherapy (oxaliplatin and capecitabine) as the first treatment for advanced stomach or gastroesophageal junction cancer that cannot be removed by surgery. The goal is to see if the combination helps shrink tumors and control the cancer better than standard care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced stomach or gastroesophageal junction cancer that cannot be removed with surgery or has spread to other parts of the body.
- You have at least one tumor that can be measured on an imaging scan (like CT or MRI).
- You have not received any previous chemotherapy or other systemic treatment for your advanced cancer.
- You do not have a known allergy to the study drugs (QLS31905, QL2107, oxaliplatin, or capecitabine).
- You have not had another cancer in the last 5 years (except for some skin cancers or early-stage cervical cancer).
- You have not had significant bleeding in the past 3 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called ASP2138 combined with chemotherapy and pembrolizumab for people with advanced stomach or gastroesophageal junction cancer that cannot be removed by surgery or has spread. It may help if your tumor has certain markers (CLDN18.2 and PD-L1) and you haven't had prior chemotherapy for advanced disease.
This trial tests a new combination of immunotherapy drugs (AK129 and cadonilimab) plus chemotherapy for people with advanced stomach or GEJ cancer who have not had treatment before. The goal is to see if adding these immunotherapies helps shrink tumors or slow cancer growth better than chemotherapy alone.
This clinical trial is testing a combination of two immunotherapy drugs (AK104 and AK112) plus chemotherapy as the first treatment for advanced stomach or gastroesophageal junction cancer. It aims to see if this combination helps control the cancer better than standard therapy.
This trial compares a new drug combination (QLS31905 plus CAPOX chemo) with another combination (sintilimab plus CAPOX) as a first treatment for advanced stomach cancer. The goal is to see which approach works better.
This trial tests a new drug called QLS31905 combined with chemotherapy, with or without another drug QL2107, for people with advanced bile duct cancer that has not been treated before. It aims to see if these combinations are safe and help shrink tumors.
This trial tests a new drug called QLS5132, alone or in combination, for people with advanced solid tumors that have not responded to other treatments. The goal is to see if it can shrink tumors or slow their growth.
Hear when a new Gastric Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.